Trials / Completed
CompletedNCT05682560
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- StemCyte, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
Detailed description
This is a two-arm, single-center, single-blind, randomized, placebo-controlled phase IIa study. A total of 30 subjects with post-COVID will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | REGENECYTE | HPC, Cord Blood |
| BIOLOGICAL | Placebo | Normal Saline |
Timeline
- Start date
- 2023-05-04
- Primary completion
- 2024-07-26
- Completion
- 2025-02-27
- First posted
- 2023-01-12
- Last updated
- 2025-03-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05682560. Inclusion in this directory is not an endorsement.